CUA Health signs contract extension with Flamingo Ai

Published 31-OCT-2018 16:40 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Flamingo Ai Limited (ASX:FGO) has inked a contract extension with major client, CUA Health Ltd (a subsidiary of Credit Union Australia), to extend its use of FGO’s Cognitive Virtual Sales Assistant, ‘Sam’.

Sam guides CUA Health’s customers through their full health insurance purchase experience and transaction. The insurance provider has been trialling Sam live with potential health insurance customers for the past two months.

Based on encouraging results, CUA Health has decided to bring forward the end of the trial date (12 November) and sign an extension of contract with FGO — inclusive of a monthly subscription fee for the Virtual Sales Assistant for health insurance, effective immediately.

FGO stated in its announcement that the details of the monthly fee are commercially sensitive.

The relationship has considerable potential for FGO’s growing sales pipeline, and validates its technology since CUA is a key player in the small cap’s target insurance market.

During the newly announced extension of the trial, CUA Health will explore opportunities to expand the health insurance pilot of Sam to new sales distribution scenarios and determine whether there may be other future use cases for the tech play within the broader business.

“We have seen some excellent early results from guiding members through the online purchase journey. Sales conversion has improved and Sam is now able to sell policies independently when appropriate to do so,” CUA Health National Sales & Marketing Manager, Richard Martin, said.

“A longer period of analysis, based on the extended pilot, will allow us to seek further improvements in member experience and conversion, plus test the technology in a different environment.”

CUA Head of Digital Innovation, Melissa Witheriff, added: “Exploration of new technologies such as AI and Machine learning are part of our digital innovation strategy. CUA has placed significant focus on investing in innovation and seeking out collaborative opportunities with partners.

“Working with the Flamingo Ai team has enabled our health business to respond to changing consumer expectations through human centred design. By enhancing the online experience for consumers inquiring about health insurance, we’ve created an engaging digital channel to attract new members to CUA Health.”

Chief Commercial Officer and Executive Director, Mark Kehoe, also had something to say about today’s major news, reaffirming that the company’s relationship with CUA has never been stronger.

“The deployment of Flamingo’s technology, and the encouraging results we are seeing, have meant that CUA and Flamingo Ai can now plan where this technology may solve problems and add value across CUA’s broader business,” he said.

“In our experience CUA have proven to be highly innovative and have their own customer’s experience being at the heart of what they do. These shared corporate values make for a strong and exciting collaboration between CUA and Flamingo Ai.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X